Table 1.
Baseline characteristics of all study subjects; subjects 18–70 and of EORTC phase III cohort
| Characteristics | RT + TMZ + Poly-ICLC (all subjects) (n = 97) | RT + TMZ + Poly-ICLC (ages 18–70) only) (n = 83) | EORTC phase III (ages 18–70) (n = 287) |
|---|---|---|---|
| Age, yr | |||
| Median | 56.6 | 55 | 56 |
| Range | 21–85 | 21–69 | 19–70 |
| Sex, n (%) | |||
| Male | 60 (62) | 51 (61) | 185 (64) |
| Female | 37 (38) | 32 (39) | 102 (36) |
| Karnofsky performance | WHO PS (n, [%]) | ||
| 100 | 34 (35) | 33 (40) | 0, 113 (39) |
| 90 | 45 (46) | 36 (43) | 1, 136 (47) |
| 80 | 12 (12) | 9 (11) | |
| 70 | 3 (3) | 3 (4) | 2, 38 (13) |
| 60 | 3 (3) | 2 (2) | |
| Extent of surgery, n (%) | |||
| Biopsy | 18 (19) | 17 (20) | 48 (17) |
| Craniotomy | 79 (81) | 66 (80) | 239 (83) |
| Time from diagnosis to radiotherapy (weeks) | |||
| Median | 4.4 | 4.4 | 5 |
| Range | 2–12.6 | 2–12.6 | 1.7–10.7 |
| Baseline MMSE score, n (%) | |||
| 30 | 56 (57) | 54 (65) | 100 (35) |
| 27–29 | 30 (31) | 22 (27) | 96 (33) |
| ≤26 | 11 (11) | 7 (8) | 81 (28) |
| Data missing | 10 (3) | ||
| Corticosteroid therapy, n (%) | |||
| Yes | 70 (72) | 61 (74) | 193 (67) |
| No | 26 (27) | 21 (26) | 94 (33) |
| Data missing | 1 (1) | ||
| Histological diagnosis, n (%) | |||
| Glioblastoma | 94 (97) | 80 (96) | 221 (92) |
| AA | 1 (1) | 1 (1.2) | 7 (3) |
| Inconclusive | 3 (1) | ||
| Other | 2 (2) | 2 (2) | 8 (3) |
Abbreviations: RT, radiation therapy; TMZ, temozolomide; MMSE, Mini-Mental Status Examination; AA, anaplastic astrocytoma.